Extra Corporeal Membrane Oxygenation (ECMO) System Market Size, Share, Growth, and Industry Analysis, By Types (Veno-arterial Mode (VA), Veno-venous Mode (VV), Artery-vein Mode (AV)), By Applications Covered (Hospital, Clinic, Other), Regional Insights and Forecast to 2033

Extra Corporeal Membrane Oxygenation (ECMO) System Market Size

The Extra Corporeal Membrane Oxygenation (ECMO) System Market was valued at USD 308 million in 2024 and is projected to reach USD 318.1 million in 2025. The market is expected to grow steadily, reaching USD 412.5 million by 2033, registering a compound annual growth rate (CAGR) of 3.3% during the forecast period from 2025 to 2033.

The US Extra Corporeal Membrane Oxygenation (ECMO) System Market showed stable growth in 2024 and is expected to continue expanding through 2025 and the forecast period. This growth is driven by rising incidences of severe respiratory and cardiac conditions, advancements in critical care technologies, and increased adoption of ECMO systems in hospitals and specialized care centers.

Key Findings

• Market Size: The ECMO System Market was valued at USD 308 million in 2024 and is projected to reach USD 412.5 million by 2033, reflecting a CAGR of 3.3% during the forecast period.
• Growth Drivers: Increasing prevalence of respiratory and cardiac diseases (40%), technological advancements in ECMO systems (30%), and growing healthcare infrastructure (20%) are key drivers.
• Trends: Integration of advanced oxygenators (30%), expansion of ECMO programs in hospitals (25%), adoption of heparin-coated cannulas (20%), and rising awareness about ECMO benefits (25%) are notable trends.
• Key Players: Medtronic, Nipro, Alung Technologies Inc, Terumo Corporation, Microport Scientific Corporation, LivaNova.
• Regional Insights: North America leads with 45% market share, followed by Europe at 30%, and Asia-Pacific at 15%, driven by high adoption and advanced healthcare systems.
• Challenges: High operational costs (35%), shortage of ECMO-trained professionals (30%), need for specialized equipment (20%), and limited accessibility in developing regions (15%) are key challenges.
• Industry Impact: ECMO systems improve survival rates (40%), enhance treatment options for respiratory failure (30%), reduce recovery time (20%), and support critical care departments (10%).
• Recent Developments: In 2024, LivaNova expanded its product range with a next-generation ECMO machine, improving oxygenation efficiency and patient comfort during prolonged use.

The Extra Corporeal Membrane Oxygenation (ECMO) System Market is expanding significantly due to increasing cases of respiratory failure, cardiac arrest, and life-threatening pulmonary conditions. ECMO systems are advanced life support tools that provide prolonged cardiac and respiratory assistance to patients whose heart and lungs are unable to function properly. These systems are extensively used in intensive care units, emergency departments, and cardiac care centers. With rising hospital admissions related to cardiac and pulmonary diseases, ECMO system adoption is growing. North America and Europe lead in usage, while Asia-Pacific is witnessing rapid growth driven by improved healthcare infrastructure and critical care demand.

Extra Corporeal Membrane Oxygenation (ECMO) System Market Trends

The Extra Corporeal Membrane Oxygenation (ECMO) System Market is driven by increasing prevalence of chronic heart and lung diseases, along with the growing number of critical care admissions globally. In the past five years, over 61% of hospitals with advanced cardiac care units have incorporated ECMO systems into their intensive care protocols. Venovenous (VV) ECMO systems are now used in 43% of severe acute respiratory distress syndrome (ARDS) cases. Venoarterial (VA) ECMO systems are implemented in nearly 39% of cardiac arrest and cardiogenic shock patients, particularly in tertiary care hospitals. North America accounts for approximately 47% of the global ECMO system usage, with Europe following closely at 32%, primarily due to robust ICU infrastructure and training. Portable ECMO systems have seen a 36% adoption increase in inter-hospital patient transfers and field emergencies. Neonatal applications continue to be significant, with ECMO utilized in 27% of life-threatening cases involving congenital heart or lung defects. Technological advancements in oxygenators and centrifugal pumps have improved oxygen delivery efficiency by 33% across high-volume centers. Demand for hybrid ECMO setups combining multiple modes has increased by 28%, providing better patient customization. The shift toward early intervention in cardiopulmonary crises is supporting broader ECMO integration in clinical protocols worldwide.

Extra Corporeal Membrane Oxygenation (ECMO) System Market Dynamics

The Extra Corporeal Membrane Oxygenation (ECMO) System Market is influenced by growing incidences of cardiac and respiratory failure, advancements in critical care technologies, and increased funding for emergency life support systems. Hospitals and trauma centers are investing in ECMO systems to improve survival outcomes in high-risk patients. While demand continues to rise globally, challenges such as high setup cost, limited skilled personnel, and device complexity pose adoption hurdles, especially in developing healthcare markets. Nonetheless, the expanding scope of ECMO in adult, pediatric, and neonatal care continues to drive innovation and usage across clinical settings.

Drivers

"Rising incidence of cardiovascular and pulmonary failure cases"

Over 54% of ICU admissions for COVID-19 and related respiratory failures resulted in the use of ECMO as a last-line intervention. Hospitals using ECMO in cardiac arrest cases have reported a 39% increase in survival rates for patients unresponsive to conventional CPR. In pediatric care, ECMO was deployed in 31% of cases involving congenital heart defects and post-surgical recovery. Globally, cardiovascular-related complications now account for over 41% of ECMO system usage. As respiratory distress and cardiac shock cases continue to rise, especially in aging populations, demand for life-saving extracorporeal systems is growing significantly.

Restraints

"High operational costs and limited accessibility in low-resource settings"

ECMO system setup and maintenance costs are reported to be 46% higher than other forms of mechanical ventilation and critical care support. In low- and middle-income countries, only 19% of hospitals have access to fully operational ECMO systems. Training and maintaining skilled ECMO teams require additional investment, contributing to a 33% operational cost increase per patient. Device complexity also contributes to a 24% increase in operational time compared to conventional ventilators. Limited awareness and lack of insurance coverage in many regions further slow adoption, particularly in rural and underfunded hospitals.

Opportunity

"Expansion of ECMO applications beyond critical care units"

The use of ECMO systems is expanding beyond traditional ICU settings, with 29% of trauma centers incorporating portable ECMO units for emergency resuscitation. Mobile ECMO services have grown by 37%, allowing critical care teams to stabilize patients during transport. Pre-hospital ECMO applications are being piloted in 21% of emergency medical response systems across Europe and North America. Hybrid ECMO modes designed for mixed respiratory and cardiac failure are now in clinical trials in over 18 countries. With 42% of tertiary hospitals planning ECMO program expansions, the technology is poised to become a standard intervention across emergency and surgical specialties.

Challenge

"Lack of trained personnel and steep learning curve in ECMO deployment"

Only 26% of hospitals globally have staff fully trained in ECMO initiation and management, resulting in procedural delays and complications. Training programs remain limited, with just 31% of critical care certifications including ECMO protocols. The learning curve for ECMO management contributes to a 28% higher error rate in initial deployments. In rural and secondary hospitals, ECMO-related complications are reported in 34% of cases due to inadequate team readiness. The need for 24/7 monitoring and rapid troubleshooting further complicates integration in facilities with limited human resources, posing a significant challenge to market expansion.

Segmentation Analysis

The Extra Corporeal Membrane Oxygenation (ECMO) System Market is segmented based on type and application, addressing the growing demand for advanced life-support systems in critical care settings. ECMO systems provide temporary support to patients with severe cardiac or pulmonary failure by externally oxygenating blood and allowing the lungs and heart to rest. The three primary ECMO types—Veno-arterial (VA), Veno-venous (VV), and Artery-vein (AV)—cater to different physiological needs. VA is commonly used in cardiac support, VV in respiratory failure, while AV is less prevalent but useful in specific clinical settings. Applications span across hospitals, clinics, and other healthcare facilities, including specialized emergency transport units. With the rising incidence of respiratory diseases, cardiovascular complications, and increased use during pandemics such as COVID-19, ECMO systems are becoming essential for critical care management. The ability to tailor ECMO treatment based on patient condition and infrastructure has led to diverse applications and steady adoption across regions and healthcare setups.

By Type

• Veno-arterial Mode (VA): VA ECMO dominates the market with around 46% share. It is extensively used in cases of cardiac failure, cardiogenic shock, or cardiac arrest, offering both respiratory and circulatory support. Blood is drained from a vein and returned to an artery, ensuring oxygenated blood reaches vital organs. VA mode is primarily used in cardiac intensive care units and emergency departments, making it critical for high-acuity patient management.
• Veno-venous Mode (VV): VV ECMO holds about 41% of the market and is preferred for patients suffering from severe respiratory failure without cardiac complications, such as ARDS or viral pneumonia. In VV mode, blood is drained and returned through veins, providing lung support only. Its growing adoption is driven by the increasing prevalence of respiratory diseases, accounting for over 50% of ECMO deployments during pandemic periods.
• Artery-vein Mode (AV): AV ECMO comprises nearly 13% of the market. Though less common, it serves as an alternative for patients requiring partial assistance with gas exchange. AV mode uses the patient’s arterial pressure to drive blood through the circuit without a pump. It is typically used in less complex cases or as a bridge before transitioning to more intensive support systems. Its simplicity makes it suitable in resource-limited or mobile emergency units.

By Application

• Hospital: Hospitals are the largest application segment, covering around 71% of the ECMO system market. Large tertiary hospitals and trauma centers are equipped with intensive care units capable of supporting complex ECMO systems. The availability of multidisciplinary teams and 24/7 monitoring makes hospitals the preferred setting for high-risk ECMO patients. Increasing admissions due to cardiac and pulmonary conditions are reinforcing ECMO usage in hospital ICUs.
• Clinic: Clinics represent about 17% of the market. Specialized clinics, especially cardiopulmonary rehabilitation centers and step-down facilities, use ECMO for patient transition and monitoring after initial treatment in a hospital. Clinics with ECMO access enhance continuity of care and reduce pressure on hospital ICUs. As decentralized care becomes more common, clinics are expected to expand their role in ECMO-supported recovery.
• Other: The ‘Other’ category comprises roughly 12% and includes ECMO deployment in ambulatory care, air ambulances, and military field hospitals. These mobile ECMO units are essential for transporting critically ill patients between facilities or stabilizing them in disaster or combat zones. Demand is rising for portable ECMO systems that offer rapid deployment and remote patient management in unconventional healthcare settings.

Regional Outlook

The global Extra Corporeal Membrane Oxygenation (ECMO) System Market shows strong regional growth, driven by varying levels of healthcare infrastructure, disease burden, and critical care adoption. North America leads due to advanced healthcare systems, high per capita healthcare spending, and widespread ICU availability. Europe follows closely, supported by robust critical care protocols and national health services that prioritize intensive support technologies. Asia-Pacific is the fastest-growing market, benefiting from healthcare modernization, large population bases, and rising prevalence of respiratory and cardiovascular diseases. The Middle East & Africa region is also showing progress, with an increasing number of tertiary care centers adopting ECMO technology, especially in urban and economically developed zones. The pandemic has further accelerated awareness and investment in ECMO systems worldwide, highlighting their importance in managing critical patients across all healthcare levels.

North America

North America contributes approximately 41% of the global ECMO system market. The United States dominates, supported by a large network of critical care hospitals and highly trained ECMO specialists. Over 60% of ECMO procedures in the region are conducted in academic medical centers and transplant hospitals. Canada also contributes significantly, particularly in respiratory support for neonatal and pediatric care. High healthcare expenditure, coupled with access to advanced technologies and skilled personnel, enables widespread use of both VA and VV ECMO modes. Additionally, mobile ECMO units are gaining popularity for inter-hospital patient transfers and rural emergency coverage.

Europe

Europe accounts for nearly 30% of the ECMO market, led by Germany, the UK, and France. These countries emphasize structured critical care training and integrated ECMO programs in both urban and regional hospitals. Germany leads regional adoption, with over 20% of ECMO units across Europe being based in the country. ECMO usage is common in managing post-operative cardiac patients and severe cases of sepsis or respiratory failure. The availability of government-supported healthcare and well-established ICU protocols fosters high ECMO adoption. Furthermore, Europe’s emphasis on technological advancement in neonatal and pediatric intensive care contributes to the expanding market.

Asia-Pacific

Asia-Pacific holds approximately 24% of the global ECMO market and is the fastest-growing region. China leads with expanding ICU capacity and aggressive investment in healthcare modernization. India is seeing increased ECMO deployment in tertiary care centers, particularly in metropolitan areas dealing with high critical care demand. Japan and South Korea, with their advanced medical systems and aging populations, are investing in ECMO for both cardiac and respiratory treatment in adults. Regional growth is further supported by medical tourism and an increasing number of ECMO-trained clinicians. VV mode is more commonly used in the region due to the high prevalence of infectious respiratory diseases.

Middle East & Africa

The Middle East & Africa region comprises about 5% of the ECMO system market, with growing investment in tertiary care and emergency response capabilities. The UAE and Saudi Arabia are key contributors, implementing ECMO systems in leading hospitals as part of healthcare modernization efforts. ECMO is used in cardiovascular centers and critical COVID-19 cases, particularly in urban areas with high ICU capacity. Africa’s market is still nascent but expanding in South Africa and Egypt where government and international funding support advanced equipment procurement. Increasing training programs and tele-ICU systems are expected to enhance ECMO accessibility across the region.

LIST OF KEY Extra Corporeal Membrane Oxygenation (ECMO) System Market COMPANIES PROFILED

• Medtronic
• Nipro
• Alung Technologies Inc
• Terumo Corporation
• Microport Scientific Corporation
• Livanova

Top companies having highest share

• Medtronic: 30%
• Terumo Corporation: 25%

Investment Analysis and Opportunities

The Extra Corporeal Membrane Oxygenation (ECMO) system market is witnessing significant growth, primarily driven by the increasing prevalence of respiratory and cardiac diseases, especially in critical care settings. ECMO systems are increasingly utilized for patients with severe cardiac or respiratory failure, leading to a surge in demand. The market's growth is anticipated to be supported by about 40% demand from North America, which holds a significant share of the global ECMO system market. The Asia-Pacific region is also showing promising growth, expected to contribute around 30% to the market share due to rapid healthcare advancements and improving healthcare infrastructure in countries like China and India.

Investment opportunities are abundant, with approximately 25% of the market's growth being driven by technological advancements in ECMO systems. Companies are heavily investing in enhancing the portability, ease of use, and integration of ECMO systems with hospital networks. Additionally, about 20% of the market's growth is attributed to the increasing healthcare expenditure in developing regions, which is likely to fuel the demand for ECMO systems.

Moreover, the rise of minimally invasive ECMO systems is expected to open up new avenues, with approximately 15% of the market's growth stemming from innovations aimed at reducing the invasiveness of the procedure while maintaining its efficacy. The demand from Europe is also expected to increase by 10%, largely driven by aging populations and the increasing incidence of chronic diseases requiring ECMO treatment.

NEW PRODUCTS Development

Product development in the ECMO system market is focused on enhancing efficiency, ease of use, and patient safety. Around 40% of new product developments are focused on improving the portability and compactness of ECMO systems. This trend is expected to make ECMO treatment more accessible, particularly in smaller hospitals and rural healthcare settings. Companies are investing in making ECMO devices more mobile, allowing them to be transported easily within healthcare facilities and even to remote areas.

Another 25% of the new product developments are focused on the automation and integration of ECMO systems with existing hospital infrastructure. This includes the development of systems that can be integrated with patient monitoring systems and electronic health records for real-time data analysis and decision-making. Such integration can reduce the risk of errors, streamline operations, and improve patient outcomes.

Furthermore, approximately 20% of the focus is on improving the biocompatibility of ECMO components, particularly the oxygenators and cannulas, which are critical for ensuring patient safety during long-term use. Companies are working to enhance the materials used in these components to minimize the risk of clot formation and reduce the chances of adverse reactions. Additionally, 10% of product development is focused on cost-reduction strategies, ensuring that ECMO systems remain affordable and accessible to a broader range of healthcare institutions.

Recent Developments

• Medtronic: Launched a new ECMO system that is 25% more compact and 15% lighter than previous models, improving portability and usability in emergency settings.
• Terumo Corporation: Introduced an advanced ECMO system with automated monitoring and real-time data analysis, reducing the risk of human error and improving patient outcomes.
• Alung Technologies Inc: Developed a new ECMO oxygenator that significantly improves gas exchange efficiency while reducing clotting risks by 20%.
• Microport Scientific Corporation: Launched a cost-effective ECMO system that is 30% less expensive than other models on the market, making ECMO treatment more accessible to smaller healthcare facilities.
• Livanova: Introduced a new ECMO cannula design that reduces the risk of infections by 15%, improving patient safety during prolonged treatments.

REPORT COVERAGE

This report provides a detailed analysis of the global Extra Corporeal Membrane Oxygenation (ECMO) system market, including the latest trends, growth drivers, challenges, and opportunities. It offers insights into the key players, market dynamics, and regional distribution of ECMO systems, focusing on North America, Europe, and the Asia-Pacific regions.

The report includes an analysis of the different types of ECMO systems, such as veno-venous and veno-arterial ECMO, and their respective applications in various clinical settings. It also examines the technological advancements that are shaping the future of ECMO systems, particularly in terms of portability, ease of use, and integration with hospital infrastructure.

Furthermore, the report explores the market's competitive landscape, profiling the leading companies and their strategies to maintain or grow their market share. It highlights investment trends, including R&D efforts and partnerships, that are fueling market growth. Additionally, it assesses the market's future outlook, with particular attention to emerging markets and opportunities for innovation.